Gilde Healthcare Partners invests in Moximed, Inc. - Gilde Healthcare

Gilde Healthcare Partners invests in Moximed, Inc.

29 juni 2011

Utrecht, The Netherlands – Gilde Healthcare Partners today announced an investment in Moximed® Inc  (Hayward, CA, US), a developer of minimally invasive, joint preserving solutions for patients with knee osteoarthritis.  Alongside Gilde Healthcare Partners, new investors Frazier Healthcare Ventures and GBS Venture Partners participated in a USD 43 million financing round. Current backers NEA and Morgenthaler Ventures also participated.

“We have followed Moximed for some time and believe that the timing is right to invest, since the company has demonstrated promising clinical data and is on the verge of commercializing the KineSpring® Knee Implant System in Europe”

 said Arthur Franken of Gilde Healthcare Partners.

As part of the financing, Arthur Franken from Gilde Healthcare Partners will join the Moximed Board of Directors.

About Moximed

Moximed® Inc. based in Hayward (CA, US), is dedicated to improving the standard of care for patients with osteoarthritis (OA).  OA, the most common form of arthritis, leads to a breakdown of the joint’s cartilage and often results in joint pain and loss of motion.  OA commonly affects the knees, hips, hands, or back.  Moximed is initially focused on developing minimally invasive, joint preserving solutions for patients with knee osteoarthritis.

Moximed’s lead product, the KineSpring® Knee Implant System, is targeting a gap in the current OA continuum of care.  There is a void between conservative care, such as pain medication and knee braces, and more invasive, joint-modifying procedures, such as osteotomy or joint replacement.  Many patients with moderate to severe knee OA, who are not candidates for joint replacement surgery due to age or activity levels, suffer from pain and a decreased quality of life until they become candidates for joint replacement. The KineSpring® System was designed to offer some of these patients a minimally invasive, joint preserving treatment option. For more information please visit the website at www.moximed.com

About Gilde Healthcare Partners

Netherlands-based Gilde Healthcare Partners is a transatlantic venture and growth capital firm focused on private healthcare technologies and services. It has over €400 million under management and is actively looking to lead new investments in therapeutics, diagnostics, medical devices and services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €15 million in a single portfolio company. By investing in companies with clear, achievable business models, Gilde has used its financial resources and network to create significant value for both its investors and the entrepreneurs it backs. For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.nl.

Gilde Healthcare II is supported by the European Communities Growth and Employment Initiative, MAP – ETF Start up Facility.

Meer nieuws

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
17 oktober 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15 oktober 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
14 oktober 2025